Printer Friendly

NEW FIVE-WAY FELINE VACCINE OFFERS 'UNSURPASSED' CONVENIENCE, EFFICACY AND SAFETY IN A SINGLE DOSE

 NEW FIVE-WAY FELINE VACCINE OFFERS 'UNSURPASSED'
 CONVENIENCE, EFFICACY AND SAFETY IN A SINGLE DOSE
 MENDOTA HEIGHTS, Minn., July 29 /PRNewswire/ -- Bringing your cat to the veterinarian for shots may not be the highlight of your day -- or your cat's. But, as any responsible owner knows it's important to visit your veterinarian at least once a year to have the cat vaccinated for common diseases. Now, thanks to recent government approval of a new feline vaccine, this annual obligation has become faster, easier, safer, less stressful to cats -- plus more effective in preventing disease.
 The U.S. Department of Agriculture has cleared the way for a Minnesota company to begin marketing a unique five-way feline vaccine that protects cats from feline leukemia, chlamydia and three other common feline diseases.
 Called Eclipse(R) 4+FeLV, the vaccine is unique in that it features four "modified live" antigens -- the type most veterinarians prefer for stimulating immunity to the four most common feline diseases -- plus an inactivated (or killed) antigen needed for feline leukemia virus (FeLV) protection.
 "Nearly half the vaccinated cats in the United States are already immunized with an Eclipse(R) vaccine," said Dr. James Walsh, a veterinarian with Solvay Animal Health, Inc., Mendota Heights, Minn., the company that makes the Eclipse line of vaccines.
 "With approval of the five-way vaccines, it's likely that your veterinarian will make the five-way Eclipse vaccine the cornerstone of his or her feline vaccination program because it provides the highest level or protection available in one convenient shot -- with virtually no vaccine reaction."
 In tests conducted with 1,115 cases, less than one percent of the cats immunized with the new five-way vaccine showed any symptoms (such as swelling, lethargy, vomiting, diarrhea, sneezing) that are sometimes associated with reactions to vaccinations, Walsh reported.
 Studies show the new five-way vaccine provides excellent protection against feline chlamydiosis and rhinotrachetis -- two common respiratory problems in cats. "Preventing chlamydia infection is especially important, because the causative organism, chlamydia psittaci, is transferable to humans and has been known to cause serious and painful cases of conjunctivitis," Walsh said.
 As an added benefit, the new five-way vaccine protects cats from unpredictable latent FeLV infection, in addition to the more apparent persistent and transient forms of infection.
 "Latency means a virus lies concealed in the body and is not detectable with conventional testing methods," Walsh explained. "As a result, cats that have tested negative for FeLV and have received vaccinations could still become ill months or even years later. Furthermore, healthy-looking cats harboring latent FeLV possibly could jeopardize the health of other cats."
 Solvay Animal Health, Inc., a leading marketer of feline vaccines, also announced that it was working on a six-way feline vaccine -- one that would include rabies protection. No timetable was given for its introduction, however.
 A non-technical brochure to help cat owners develop a better understanding of major feline diseases and the need for veterinary care is available from Solvay. For a free copy, send your name and address to:
 Feline Disease Brochure
 Solvay Animal Health, Inc.
 1201 Northland Drive
 Mendota Heights, Minn. 55120-1149
 For more information on the new five-way vaccine, cat owners should contact their veterinarian.
 -0- 7/29/92
 /NOTE TO EDITOR: Dr. Walsh is available for interviews./
 /CONTACT: Joseph Feeks of Feeks Wilson Communications, 914-758-2200, for Solvay Animal Health/ CO: Solvay Animal Health ST: California IN: SU:


SM -- NYPFNS2 -- 4379 07/29/92 06:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:570
Previous Article:B.A.T. INDUSTRIES ANNOUNCES MASSIVE PROFIT RISE
Next Article:GET YOUR COUCH POTATO CAT (AND YOURSELF) OFF THE COUCH
Topics:


Related Articles
CONNAUGHT LABORATORIES, INC. RECEIVES ACELLULAR DTP VACCINE LICENSE
NICHD ANNOUNCES RESULTS FROM PHASE III CLINICAL TRIAL FOR NORTH AMERICAN VACCINE'S DTaP VACCINE
SMITHKLINE BEECHAM STATEMENT ON NIAID VACCINE TRIALS SHOWING INFANRIX(TM) HIGHLY EFFECTIVE AGAINST PERTUSSIS
SMITHKLINE BEECHAM'S AUGMENTIN(R) CLEARED IN U.S. IN MORE CONVENIENT DOSING REGIMEN FOR CHILDREN
American Home Products Announces European Approval of ReFacto.
American Home Products Corporation Launches ReFacto in the United Kingdom.
Veterinarians Keep Close Watch on Potentially Deadly Canine Disease; -- New Website Profiles the Latest Info on Recent Outbreak of Leptospirosis --.
Heska Announces Launch of Feline UltraNasal(TM) Vaccines.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters